Gaby P. Smits

Ms. Gaby P. Smits


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2012 in Clinical and Vaccine Immunology
Verified
Journal Article
Open access
PDF file
GSGaby P. Smits
Gaby P. Smits
PGPieter van Gageldonk
Pieter van Gageldonk
LSLeo M. Schouls
Leo M. Schouls
FKFiona R. M. van der Klis
Fiona R. M. van der Klis
GBGuy A. M. Berbers
Guy A. M. Berbers
Enzyme-linked immunosorbent assay (ELISA) is normally used to quantify the amount of serum IgG antibodies against measles, mumps, rubella, and varicella-zoster virus (MMRV). However, this method is time- and material-consuming. Therefore, a multiplex immunoassay for the simultaneous quantitative detection of antibodies against MMRV was developed. In-house as well as commercially available antigens can be used, making the assay available for all laboratories. The multiplex assay is much more sensitive than the separate ELISAs and has a high specificity, and only 5 μl of serum is needed. Heterologous inhibition did not exceed 11.5%, while homologous inhibition varied between 91.3 and 97.9%. Good correlations with the in-house ELISAs for measles (R2= 0.98), mumps (R2= 0.97), and rubella (R2= 0.97) virus as well as with the ELISA kit for varicella-zoster virus (R2= 0.95) were obtained. In conclusion, the MMRV multiplex assay is a good alternative to the conventional ELISAs and suitable for use in serosurveillance and vaccine studies.

8 March 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GSGaby P. Smits
Gaby P. Smits
LMLiesbeth Mollema
Liesbeth Mollema
SHSusan Hahné
Susan Hahné
HMHester de Melker
Hester de Melker
ITIrina Tcherniaeva
Irina Tcherniaeva
GBGuy Berbers
Guy Berbers
Here we present mumps virus specific antibody levels in a large cross-sectional population-based serosurveillance study performed in the Netherlands in 2006/2007 (n = 7900). Results were compared with a similar study (1995/1996) and discussed in the light of recent outbreaks. Mumps antibodies were tested using a fluorescent bead-based multiplex immunoassay. Overall seroprevalence was 90.9% with higher levels in the naturally infected cohorts compared with vaccinated cohorts. Mumps virus vaccinations at 14 months and 9 years resulted in an increased seroprevalence and antibody concentration. The second vaccination seemed to be important in acquiring stable mumps antibody levels in the long term. In conclusion, the Dutch population is well protected against mumps virus infection. However, we identified specific age- and population groups at increased risk of mumps infection. Indeed, in 2007/2008 an outbreak has occurred in the low vaccination coverage groups emphasizing the predictive value of serosurveillance studies.

1 April 2014 in Vaccine
Verified
Journal Article
Closed access
GSGaby P. Smits
Gaby P. Smits
LMLiesbeth Mollema
Liesbeth Mollema
SHSusan Hahné
Susan Hahné
HMHester de Melker
Hester de Melker
ITIrina Tcherniaeva
Irina Tcherniaeva
GBGuy Berbers
Guy Berbers

17 January 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
PKPatricia Kaaijk
Patricia Kaaijk
AWAlienke J Wijmenga-Monsuur
Alienke J Wijmenga-Monsuur
HHHinke I. Ten Hulscher
Hinke I. Ten Hulscher
JKJeroen Kerkhof
Jeroen Kerkhof
GSGaby P. Smits
Gaby P. Smits
Robert van BinnendijkRobert van Binnendijk
Robert van Binnendijk
Mumps outbreaks and breakthrough infections of measles and rubella have raised concerns about waning of vaccine-induced immunity after two doses of measles-mumps-rubella (MMR) vaccination. In the present follow-up study, serum IgG antibodies against mumps, measles and rubella, as well as the functional neutralizing antibodies against both the mumps vaccine strain and mumps outbreak strains were measured longitudinally in young adults that received a third MMR (MMR3) dose. The mumps-specific IgG and virus neutralizing antibody levels at 3 years after vaccination were still elevated compared to pre-vaccination antibody levels, although the differences were smaller than at earlier timepoints. Interestingly, subjects with low antibody levels to mumps before vaccination benefited the most as they showed the strongest antibody increase after an MMR3 dose. Three years after an MMR3 dose, all subjects had antibody levels to measles and rubella above the internationally agreed antibody cutoff levels for clinical protection. Our data support the recommendation that an MMR3 dose may provide additional protection for those that have become susceptible to mumps virus infection during outbreaks. MMR3 also resulted in an increase in anti-measles and rubella antibody levels that lasted longer than might have been expected.

6 September 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
LHLotus Loenie Van Den Hoogen
Lotus Loenie Van Den Hoogen
MBMardi Boer
Mardi Boer
APAbigail Postema
Abigail Postema
LRLia de Rond
Lia de Rond
MZMary-Lène de Zeeuw-Brouwer
Mary-Lène de Zeeuw-Brouwer
ABAnnemarie Buisman
Annemarie Buisman
Vaccine-induced protection against severe COVID-19, hospitalization, and death is of the utmost importance, especially in the elderly. However, limited data are available on humoral immune responses following COVID-19 vaccination in the general population across a broad age range. We performed an integrated analysis of the effect of age, sex, and prior SARS-CoV-2 infection on Spike S1-specific (S1) IgG concentrations up to three months post-BNT162b2 (Pfizer/BioNTech; Comirnaty) vaccination. In total, 1735 persons, eligible for COVID-19 vaccination through the national program, were recruited from the general population (12 to 92 years old). Sixty percent were female, and the median vaccination interval was 35 days (interquartile range, IQR: 35–35). All participants had seroconverted to S1 one month after two vaccine doses. S1 IgG was higher in participants with a history of SARS-CoV-2 infection (median: 4535 BAU/mL, IQR: 2341–7205) compared to infection-naive persons (1842 BAU/mL, 1019–3116), p < 0.001. In infection-naive persons, linear mixed effects regression showed a strong negative association between age and S1 IgG (p < 0.001) across the entire age range. Females had higher S1 IgG than males (p < 0.001). In persons with an infection history, age nor sex was associated with S1 IgG concentrations. The lower magnitude of S1 antibodies in older persons following COVID-19 vaccination will affect long-term protection.

29 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JSJuliette Schmidt
Juliette Schmidt
NDNoël M. M. Dautzenberg
Noël M. M. Dautzenberg
PHPeter M. Hoogerbrugge
Peter M. Hoogerbrugge
CLCaroline Lindemans
Caroline Lindemans
SNStefan Nierkens
Stefan Nierkens
WTWim J. E. Tissing
Wim J. E. Tissing
COVID-19 vaccinations are recommended for children with cancer but data on their vaccination response is scarce. This study assesses the antibody and T-cell response following a 2- or 3-dose vaccination with BNT162b2 mRNA COVID-19 vaccine in children (5–17 years) with cancer. For the antibody response, participants with a serum concentration of anti-SARS-CoV-2 spike 1 antibodies of >300 binding antibody units per milliliter were classified as good responders. For the T-cell response, categorization was based on spike S1 specific interferon-gamma release with good responders having >200 milli-international units per milliliter. The patients were categorized as being treated with chemo/immunotherapy for less than 6 weeks (Tx < 6 weeks) or more than 6 weeks (Tx > 6 weeks) before the first immunization event. In 46 patients given a 2-dose vaccination series, the percentage of good antibody and good T-cell responders was 39.3% and 73.7% in patients with Tx < 6 weeks and 94.4% and 100% in patients with Tx > 6 weeks, respectively. An additional 3rd vaccination in 16 patients with Tx < 6 weeks, increased the percentage of good antibody responders to 70% with no change in T-cell response. A 3-dose vaccination series effectively boosted antibody levels and is of value for patients undergoing active cancer treatment.